Cytosorbents Co. (NASDAQ:CTSO) Position Increased by Sargent Investment Group LLC

Sargent Investment Group LLC grew its holdings in Cytosorbents Co. (NASDAQ:CTSO) by 13.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,626,247 shares of the medical research company’s stock after purchasing an additional 192,747 shares during the period. Sargent Investment Group LLC owned about 2.99% of Cytosorbents worth $2,439,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter valued at about $51,000. CM Management LLC raised its stake in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Avenir Corp raised its stake in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analysts Set New Price Targets

CTSO has been the topic of several research analyst reports. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th. StockNews.com initiated coverage on Cytosorbents in a report on Sunday. They issued a “hold” rating for the company. Finally, HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday.

Cytosorbents Stock Performance

Shares of CTSO stock traded up $0.06 on Thursday, reaching $0.99. The stock had a trading volume of 12,786 shares, compared to its average volume of 124,879. The stock has a market cap of $54.11 million, a P/E ratio of -2.57 and a beta of 0.56. Cytosorbents Co. has a 1 year low of $0.70 and a 1 year high of $2.15. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97. The company has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.01.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. During the same period in the previous year, the firm posted ($0.14) earnings per share. Equities research analysts expect that Cytosorbents Co. will post -0.31 EPS for the current year.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.